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Exposure and covariates
Main exposure: tumor hrHPV status (hrHPV+ vs. hrHPV-)  HPV genotyping: L1 region  13 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)  HPV types not established as oncogenic (low-risk types) (HPV 6, 11, 26, 30, 40, 42, 43, 53, 54, 61, 66, 67, 69, 70, 73, 74, 81, 82, 83, 86, 87, 89, 90, 91) Other covariates:
 Age at cancer diagnosis (<30, 30-44, 45-59, 60-74  unsatisfactory material for representative HPV genotyping, as determined by senior pathologist review of HPV-negative diagnostic FFPE samples.
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MEASUREMENTS AND VARIABLES
Outcome variable
All causes of death in case women, collected from the Total Population Registry 1=yes/death, 0=no/alive.
Exposure and covariates
Main exposure: tumor hrHPV status (hrHPV+ vs. hrHPV-)  HPV genotyping: L1 region  13 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)  HPV types not established as oncogenic (low-risk types) (HPV 6, 11, 26, 30, 40, 42, 43, 53, 54, 61, 66, 67, 69, 70, 73, 74, 81, 82, 83, 86, 87, 89, 90, 91) Other covariates: Since loss of the L1 region could occur in tumors, whereas the oncogenic E7 and E6 regions are more likely to be retained. HPV16-E7 and HPV18-E6 real-time (RT) PCR results will be performed on all L1-negative samples, and the results included as sensitivity analysis in same manner as analysis based on Luminex results.
Representativeness of the diagnostic blocks for cancer cases 2002-2011
Compare the availablity of FFPE blocks in all biobanks in Sweden to ensure the samples. 
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